Repligen Corp
RGEN121.658USD
+1.428+1.19%
Horário de mercado （ET）Cotações atrasadas em 15 min
6.84BValor de mercado
PerdaP/L TTM
Mais detalhes de Repligen Corp Empresa
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Informações da empresa
Código da empresaRGEN
Nome da EmpresaRepligen Corp
Data de listagemApr 29, 1986
CEOMr. Olivier Loeillot
Número de funcionários1778
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 29
EndereçoBuilding 1, Suite 100
CidadeWALTHAM
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02453
Telefone17814499560
Sitehttps://www.repligen.com/
Código da empresaRGEN
Data de listagemApr 29, 1986
CEOMr. Olivier Loeillot
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
91.29K
+1.08%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
32.55K
+3.08%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
14.31K
-14.90%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
12.56K
+147.18%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
4.94K
+24.53%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
3.32K
+41.49%
Dr. Konstantin Konstantinov, Ph.D.
Dr. Konstantin Konstantinov, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jason K. Garland
Mr. Jason K. Garland
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Tony John Hunt
Mr. Tony John Hunt
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Martin D. Madaus, Ph.D.
Dr. Martin D. Madaus, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
91.29K
+1.08%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
32.55K
+3.08%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
14.31K
-14.90%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
12.56K
+147.18%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
4.94K
+24.53%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
3.32K
+41.49%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
North America
84.59M
50.00%
Europe
59.21M
35.00%
APAC/Other
25.38M
15.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.00%
BlackRock Institutional Trust Company, N.A.
8.37%
T. Rowe Price Associates, Inc.
6.10%
Roy T. Eddleman UEO
5.89%
Point72 Asset Management, L.P.
3.40%
Outro
67.25%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.00%
BlackRock Institutional Trust Company, N.A.
8.37%
T. Rowe Price Associates, Inc.
6.10%
Roy T. Eddleman UEO
5.89%
Point72 Asset Management, L.P.
3.40%
Outro
67.25%
Tipos de investidores
Investidores
Proporção
Investment Advisor
59.57%
Investment Advisor/Hedge Fund
25.36%
Hedge Fund
13.00%
Individual Investor
6.39%
Research Firm
2.39%
Pension Fund
2.37%
Bank and Trust
0.68%
Sovereign Wealth Fund
0.59%
Family Office
0.50%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
1028
61.98M
110.32%
-3.21M
2025Q1
1054
62.91M
111.98%
-2.72M
2024Q4
1054
61.13M
109.11%
-3.76M
2024Q3
1046
60.75M
108.48%
-6.10M
2024Q2
1039
61.28M
109.67%
-2.73M
2024Q1
1036
60.56M
108.45%
-5.41M
2023Q4
1062
62.13M
111.29%
-2.30M
2023Q3
1063
61.47M
110.27%
+2.91M
2023Q2
1050
59.01M
105.99%
+1.34M
2023Q1
1061
58.23M
104.67%
+1.01M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
5.07M
9.02%
-21.20K
-0.42%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.89M
8.7%
+13.96K
+0.29%
Mar 31, 2025
T. Rowe Price Associates, Inc.
7.52M
13.38%
+427.74K
+6.03%
Mar 31, 2025
Roy T. Eddleman UEO
3.31M
5.89%
-67.50K
-2.00%
Dec 31, 2024
Point72 Asset Management, L.P.
1.12M
1.99%
+197.82K
+21.53%
Mar 31, 2025
State Street Global Advisors (US)
1.69M
3.01%
-2.27K
-0.13%
Mar 31, 2025
Champlain Investment Partners, LLC
1.46M
2.61%
-79.53K
-5.15%
Mar 31, 2025
Sands Capital Management, LLC
1.29M
2.3%
-70.06K
-5.14%
Mar 31, 2025
Invesco Advisers, Inc.
1.60M
2.84%
+768.85K
+93.02%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Alger Mid Cap 40 ETF
4.16%
First Trust NYSE Arca Biotechnology Index Fund
3.18%
Invesco Biotechnology & Genome ETF
2.7%
BNY Mellon Innovators ETF
2.6%
iShares Health Innovation Active ETF
1.64%
VanEck Biotech ETF
1.39%
Franklin Genomic Advancements ETF
1.24%
Congress SMid Growth ETF
1.24%
WisdomTree BioRevolution Fund
1%
Pacer US Export Leaders ETF
0.93%
Ver Mais
Alger Mid Cap 40 ETF
Proporção4.16%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.18%
Invesco Biotechnology & Genome ETF
Proporção2.7%
BNY Mellon Innovators ETF
Proporção2.6%
iShares Health Innovation Active ETF
Proporção1.64%
VanEck Biotech ETF
Proporção1.39%
Franklin Genomic Advancements ETF
Proporção1.24%
Congress SMid Growth ETF
Proporção1.24%
WisdomTree BioRevolution Fund
Proporção1%
Pacer US Export Leaders ETF
Proporção0.93%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
